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Abstract
Background: The p53 tumor suppressor gene is mutated in about half of human cancers, but the p53 pathway is thought to
be functionally inactivated in the vast majority of cancer. Understanding how tumor cells can become insensitive to p53
activation is therefore of major importance. Using an RNAi-based genetic screen, we have identified three novel genes that
regulate p53 function.
Results: We have screened the NKI shRNA library targeting 8,000 human genes to identify modulators of p53 function. Using
the shRNA barcode technique we were able to quickly identify active shRNA vectors from a complex mixture. Validation of the
screening results indicates that the shRNA barcode technique can reliable identify active shRNA vectors from a complex pool.
Using this approach we have identified three genes, ARNTL, RBCK1 and TNIP1, previously unknown to regulate p53 function.
Importantly, ARNTL (BMAL1) is an established component of the circadian regulatory network. The latter finding adds to recent
observations that link circadian rhythm to the cell cycle and cancer. We show that cells having suppressed ARNTL are unable to
arrest upon p53 activation associated with an inability to activate the p53 target gene p21
CIP1.
Conclusions: We identified three new regulators of the p53 pathway through a functional genetic screen. The identification
of the circadian core component ARNTL strengthens the link between circadian rhythm and cancer.
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Introduction
The TP53 gene product is important in the cellular response to
different types of stress [1,2]. A major physiological stress is DNA
damage. DNA damage leads to activation of the ATM/ATR,
CHK1/2 cascade, which in turn activates p53. Activation of p53 is
achieved by increased stability and post translational modifications
of the p53 protein. These modifications include phosphorylation,
methylation [3], ubiquitination [4,5] and acetylation [6] leading to
enhanced transcriptional activity of p53. Furthermore, oncogene
activation can also lead to p53 activation through activation of the
p19
ARF protein. p19
ARF inhibits MDM2, the major E3 ubiquitin
ligase for p53 [7] leading to stabilization and activation of p53.
Activation of p53 leads to transcriptional activation of a large set of
p53 target genes, which in turn causes cell cycle arrest or apoptosis
[8].
The p53 pathway is inactivated in almost all human cancers [9].
In about half of human cancers this is due to mutation or deletion
of the TP53 gene itself. However in a significant fraction of human
tumors, the p53 pathway is inactivated through alteration in
cellular components acting up- or down-stream of p53. For
example, amplification of the negative regulator of p53, MDM2,
leads to accelerated degradation and inactivation of p53 [2,10].
As a model to screen for genes that modulate p53 function, we
previously developed a human fibroblast cell line named BJtsLT
[11]. These cells express a temperature-sensitive mutant of the
SV40 large T antigen, which allows the cells to proliferate at the
permissive temperature (32uC). However, when the cells are
shifted to 39uC, the large T antigen is degraded and the cells enter
a stable p53-dependent cell cycle arrest.
We and others have previously described the construction and
initial screening of shRNA libraries using the barcode technique
[11–17]. The barcode technique allows the rapid identification of
individual shRNA vectors from a large pool of shRNA vectors that
produce a specific phenotype. This approach takes advantage of
the fact that each shRNA vector contains a unique 19-mer
sequence as part of the shRNA cassette, which can serve as a
molecular ‘‘barcode’’ identifier. Briefly, cells are infected with the
pooled shRNA library of some 24,000 vectors. The population of
cells is then split into two separate populations. One population is
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selective treatment. Knockdown of a specific gene by the shRNA
vector can lead to three possible cellular responses to this
treatment. First the cells can remain unaffected identical to
control cells, second the cells can become more sensitive to the
treatment and third the cells can acquire resistance to the
treatment. As a consequence of the differential response to the
treatment, the relative number of cells that harbor a specific
shRNA can increase, decrease or remain the same. The relative
abundance of each shRNA cassette can be determined by the
isolation of the shRNA cassettes from the population, labeling of
the barcode identifiers with different fluorescent dyes and
subsequent hybridization to DNA microarrays representing all
shRNA sequences. By comparing the relative abundance of all
shRNAs against the reference population, shRNAs responsible for
the three possible phenotypes can be identified.
The shRNA barcode technique can be used for different
screening approaches, most notably the identification of genes that
are involved in drug resistance. For instance, we have used the
barcoding approach to identify genes that are involved in the
resistance to the cytotoxic effects of Nutlin-3, a drug that activates
p53 by acting as an inhibitor of MDM2 [13]. This led to the
identification of 53BP1, a p53 binding protein, as a critical
modulator of the effect of Nutlin-3. More recently, we found the
tumor suppressor PTEN as a gene, which upon decreased
expression confers resistance to trastuzumab in breast cancer
[12]. Significantly, the PI3K pathway, which is negatively
regulated by PTEN, was also shown to be a major regulator of
trastuzumab sensitivity in the clinic, underscoring the utility of the
in vitro genetic screens to identify drug modulators.
In the first screen applying the NKI shRNA library, Berns et al.
used BJtsLT cells to identify 5 new players in the p53 pathway
[11]. This screen did not take advantage of the barcode
technology. Rather, it was performed by the conventional method
of isolating and expanding colonies that are resistant to p53-
mediated growth arrest. Subsequent isolation of the shRNA inserts
and sequence analysis was required to identify the shRNA
responsible for the bypass of the p53 mediated cell cycle arrest.
This method is rather laborious and such an approach may not
uncover all active shRNAs in a library. Moreover, due to the
labour-intensive nature of the screen, only part of the 24,000
vector NKI shRNA library was covered in this initial approach.
Here we describe the screening of the entire NKI shRNA library
for modulators of p53 activity using the barcode technology. We
find three additional genes whose suppression causes resistance to
p53-dependent proliferation arrest.
Results
Screening of the BJtsLT cells
To identify shRNA vectors that can modulate the activity of the
p53 pathway, we performed a shRNA bar code screen in BJtsLT
cells infected with the NKI shRNA library (See Figure 1a). These
cells proliferate at 32uC but enter into a p53-dependent
proliferation arrest at 39uC [11]. The infected cells were cultured
for three days at 32uC to allow retroviral integration and for gene
knockdown to become effective. At day 4 the cells were split into
two populations; one was kept at 32uC and the other was shifted to
39uC. The BJtsLT at 32uC were cultured until the population
reached confluency and genomic DNA was isolated. The BJtsLT
cells grown at 39uC cease proliferation unless a shRNA is
expressed that inactivates the p53-dependent anti-proliferative
response. Such cells will continue to proliferate and give rise to a
colony. In addition to infection with the NKI shRNA library, we
also used a shRNA vector targeting p53 as a positive control for
colony outgrowth of the BJtsLT cells at 39uC. After 3 weeks of
culturing at 39uC, the control platesinfected with p53 shRNA vector
contained large numbers of colonies consisting of rapidly prolifer-
ating cells (data not shown). The plates infected with the shRNA
library also contained several colonies. Colonies from the library-
infected plates were pooled and genomic DNA was isolated. The
shRNA cassettes were recovered from the genomic DNA using
PCR. The recovered shRNA inserts from both the control
population and the colonies that continued proliferation at 39uC
following infection with the shRNA library, were used to hybridize
DNA microarrays containing all 24,000 19-mer sequences of the
NKI shRNA library. The hybridization was performed for each of
the replicate experiments, after which the results were combined to
increase the statistical significance of the enriched shRNA vectors
identified. Those shRNA vectors that confer resistance to the p53
mediated cell cycle arrest are enriched in the population cultured at
39uC and can be detected as outliers in a MA-plot representation of
the barcode microarray experiment (figure 1b).
From this MA-plot we generated a ‘‘hit list’’ of shRNA vectors
that are specifically enriched in cell cultured at 39uC. The
following considerations were used to produce this hit list
(summarized in figure 1c). We excluded all shRNAs that had an
intensity (A-value) lower than 10, as spots with a relative low
intensity are likely to be ‘‘noise’’ and as a consequence can have
aberrantly high ‘‘M’’ ratios. In addition we only included shRNAs
if their ratio (M=2log ratio cy5/cy3) was .0.75, this effectively
means the top 100 most enriched shRNAs on the micro-array.
To shorten the list of shRNA vectors to be validated, we first
asked where shRNA vectors targeting known components of the
p53 pathway were positioned in the top 100. In total, five shRNA
vectors targeting known components of the p53 pathway were
present in the top 100 and their distribution was as follows
(Table 1): one shRNA vector targeting p53 (position #8), two
shRNA vectors targeting p21
cip1 (#7&#37) and two shRNA
vectors targeting 53BP1 (#5&#36). As we identified shRNA
vectors targeting 53BP1 and p21
cip1 at positions 36 and 37 on the
hit list, we decided to individually test all shRNA vectors on
positions 1–37 in a second round selection. Included in this set are
vectors targeting 3 out of 5 genes that were previously identified
and validated by Berns et al., (2004): HDAC4 (#2) KIA0828 (#13),
HTATIP (#25). The identification of these shRNA vectors
provides further support for the notion that the barcode method
enables both fast and reliable screening of shRNA libraries.
In addition, we selected 3 genes that were represented by two
independent shRNAs in the top 100 (of which one is present in the
37 already selected shRNAs), bringing the total number of
shRNAs to be tested to 42. We included these 3 additional genes
in the validation, because if two independent shRNAs targeting
the same transcript are enriched in the shRNA screen, this gives
higher level of confidence to that specific hit. This is because it is
less likely to be ‘‘off target’’ when two independent shRNAs yield
the same phenotype and such off target effects of shRNAs are a
common problem in these types of genetic screens [18,19]. The
other three genes, ARNTL [20], RBCK1 [21] and TNIP1 [22] have
not been linked to p53 before.
To prove that the shRNA barcode technique specifically
identifies shRNAs that are enriched in the experiment we also
tested 30 randomly-selected shRNAs not enriched in the
experiment. All shRNAs were re-tested in the BJtsLT cells. Cells
were infected with individual shRNAs, shifted to 39uC and
incubated for 3 weeks. When colonies were observed the cells were
fixed and stained. As expected, none of the 30 randomly-selected
shRNAs was able to produce colonies at 39uC (data not shown).
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clearly demonstrate that they allowed the cells to proliferate at
39uC. Among the genes targeted by these 37 shRNA vectors were
all known p53 pathway components. In addition, we also observed
rescue of growth arrest by all three genes that were targeted by two
individual shRNAs: ARNTL, RBCK1 and TNIP1 (Figure 2).
Therefore we decided to focus on these three newly identified
genes for which we identified two independent shRNAs.
To show the sensitivity and selectivity of the shRNA barcode
technique, we decided to test all three shRNA vectors targeting
ARNTL, RBCK1 and TNIP1 that are present in the library. As
mentioned before, for these three genes we found only two of the
three shRNAs to be enriched in the screen, whereas one shRNA
vector was not enriched. When we infected all three shRNA vectors
independently into BJtsLT cells we found that only shRNAs enriched
in the shRNA barcode screen gave rise to colonies (Figure 2).
Figure 1. shRNA barcode screen identifies mediators of the p53 dependent cell cycle arrest. a) Schematic outline of the BJtsLT genetic
screen. BJtsLT cells were infected with the NKI shRNA library and were either left at 32uC or shifted to 39uC. After 7 days the cells at 32uC had reached
confluency and were harvested. Cells at 39uC were harvested after 23 days after which they had formed visible colonies. b) Analysis of the relative
abundance of shRNAs recovered from the BJtsLT barcode experiment. Data are normalized and plotted as M, the
2log (ratio Cy5/Cy3), versus A
(
2log(!intensity Cy36Cy5)). The data are the average of two independent hybridization experiments performed in duplicate with reversed colour. A
red box is drawn around the top 100 enriched shRNAs at 39uC. c) Schematic overview of selection criteria used to select hits from the shRNA barcode
screen for further validation.
doi:10.1371/journal.pone.0004798.g001
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Rank M A Rescue HUGO RefSeq 19mer_start 19mer_sequence Remarks
14 . 0 7 1 2 . 2 4 + KCNK9 NM_016601 217 GTACAACATCAGCAGCGAG
23 . 9 5 1 2 . 2 2 + HDAC4 NM_006037 3751 GCATGTGTTTCTGCCTTGC Berns et al
33 . 7 3 1 1 . 6 5 + ABHD6 NM_020676 374 GGATATGTGGCTCAGTGTG
43 . 6 7 1 2 . 9 8 + MYCL1 NM_005376 933 GAGACACTCCAAACCTGAA
53 . 3 9 1 1 . 4 9 + TP53BP1 NM_005657 657 GATACTGCCTCATCACAGT Known p53 pathway
63 . 3 9 1 1 . 6 0 + XRCC1 NM_006297 258 GGAGGAGCAGATACACAGT
73 . 1 8 1 0 . 7 6 + CDKN1A NM_078467 919 CTAGGCGGTTGAATGAGAG Known p53 pathway
83 . 1 4 1 2 . 1 7 + TP53 NM_000546 1026 GACTCCAGTGGTAATCTAC Known p53 pathway
93 . 0 9 1 3 . 2 0 + CALCA NM_001741 428 AGGGATATGTCCAGCGACT
10 3.00 12.03 + RBCK1 NM_031229 1389 GTCAGTACCAGCAGCGGAA this manuscript
11 2.99 12.52 + INSRR J05046 2402 GAACAGTGTCCTTCTGCGC
12 2.92 11.65 + SSR4 NM_006280 377 GAGTCCTACAGCCTCCTCA
13 2.91 12.60 + KIAA0828 NM_015328 3945 GAGTACATTCTGCCTTGCT Berns et al
14 2.91 12.83 + PTPRN2 NM_002847 2968 GAGATTGATATCGCAGCGA
15 2.63 13.86 + TCEAL1 NM_004780 386 GGACCTGTTTGAGGTTCGC
16 2.56 12.22 + LHX3 AF156888 266 GTGTCTCAAGTGCAGCGAC
17 2.47 12.12 + NR2E3 AF148128 852 GTGGGCCAAGAACCTGCCT
18 2.35 11.37 + LOC90925 BC002792 226 AGAACTGGAGTGGATGGGG
19 2.28 11.94 + MPZ NM_000530 793 GGATAAGAAATAGCGGTTA
20 2.26 11.49 + NR2E3 NM_014249 889 GTGGGCCAAGAACCTGCCT
21 2.21 11.98 + PENK NM_006211 779 GATACGGAGGATTTATGAG
22 2.12 10.78 + SLIT2 NM_004787 490 AGAGGAGCATTCCAGGATC
23 2.09 11.87 + TRAR3 NM_175057 52 GTGAACGAATCCTGCATTA
24 2.04 11.66 2 CDKN2A NM_000077 745 GAACCAGAGAGGCTCTGAG
25 2.04 11.96 + HTATIP NM_006388 1045 GTACGGCCGTAGTCTCAAG Berns et al
26 2.02 11.21 + PRPF18 NM_003675 228 AGAGGAGGACCAGAAACCA
27 2.02 11.93 2 GOLGA5 NM_005113 2209 GATACCCCATAGCGCGAGT
28 2.01 13.08 2 TIEG NM_005655 2179 GAATTGGAATCCTCCTTAA
29 1.97 11.92 2 COL12A1 NM_004370 1844 GGATGCCGTTCGCTCAGAA
30 1.94 13.07 + RAD51C NM_058216 263 GATATGCTGGTACATCTGA
31 1.85 13.70 2 TLR4 NM_003266 2180 GACCATCATTGGTGTGTCG
32 1.83 11.43 + RAB2 NM_002865 725 GAAGGAGTCTTTGACATTA
33 1.83 11.05 + ZNF347 NM_032584 387 GAGTAATACAGGAGAAGTA
34 1.82 12.01 + HSD17B4 NM_000414 142 AGAGGAGCGTTAGTTGTTG
35 1.80 11.91 2 GCGR NM_000160 547 AGTGCAACACCGCTTCGTG
36 1.75 11.19 + TP53BP1 NM_005657 387 GAACGAGGAGACGGTAATA Known p53 pathway
37 1.72 11.09 + CDKN1A NM_078467 560 GACCATGTGGACCTGTCAC Known p53 pathway
40 1.67 11.13 + RPS6KA6 NM_014496 GATTATCCAAAGAGGTTCT Berns et al
46 1.49 10.96 + RBCK1 NM_031229 710 GGGGATGAACAGGTGGCAA this manuscript
51 1.31 10.57 + TNIP1 NM_006058 1718 GGAAGAGCTGAAGAAGCAA this manuscript
59 1.23 11.67 + TNIP1 NM_006058 408 GAGTCCCAGATGGAAGCGA this mansucript
74 1.00 10.42 + ARNTL NM_001178 1468 GAACTTCTAGGCACATCGT this manuscript
99 0.76 11.55 + ARNTL NM_001178 590 GGGAAGCTCACAGTCAGAT this manuscript
Under rescue; + means a validated shRNA, 2 means not validated. M indicates the
2log (ratio Cy5/Cy3), A the
2log(!intensity Cy36Cy5).
doi:10.1371/journal.pone.0004798.t001
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Next, we investigated if the shRNA vectors targeting ARNTL,
TNIP1 and RBCK1 also reduced mRNA levels of their cognate
target genes. BJtsLT cells were infected at 32uC and shifted to
39uC 3 days after infection. When colonies appeared, RNA was
isolated and subjected to quantification by QRT-PCR. The result
from the QRT-PCR showed that enriched shRNA vectors
targeting ARNTL, RBCK1 and TNIP1 were more potent in
decreasing target mRNA than the shRNA vectors that were not
enriched (Figure 3a, 3b, 3c). In addition, we tested for both
ARNTL and TNIP1 if protein levels were also affected by the
shRNA vectors. For ARNTL we co-expressed the three shRNA
vectors together with a cDNA encoding hARNTL in Phoenix
cells. From the western blot analysis it was clear that only the
vectors that could produce colonies also induced potent knock-
down of protein expression, thus linking gene knockdown to the
p53 growth arrest bypass phenotype (Figure 3d). Knockdown of
TNIP1 was determined by analyzing endogenous protein levels in
BJtsLT cells (Figure 3e). As can be seen only the vectors that are
enriched in the barcode screen and validated to enable colony
growth at 39uC were able to reduce endogenous TNIP1 protein
levels. We conclude that by limiting the hit selection to genes that
are targeted by two independent shRNAs we have only selected
‘on-target’ hits from a complex library.
Knockdown of ARNTL, RBCK1 and TNIP1 in BJtsLT cells
leads to reduced p21
CIP1 levels
p21
CIP1 is one of the critical effectors of p53 to induce a cell cycle
arrest [23]. This is further supported by our identification of two
shRNAs targeting p21
CIP1 in the list of outliers of the BJtsLT
screen. We therefore examined the effect of knockdown of ARNTL,
RBCK1 and TNIP1 on p21
CIP1 induction. We tested the effects on
p21
CIP1 in the BJtsLT system that we used for the initial screen.
When BJtsLT cells are shifted to 39uC, a rapid increase in p21
CIP1
protein levels is observed (Figure 4a). As expected, this p21
CIP1
induction is attenuated in cells infected with shRNA vectors
targeting p53, p21
CIP1 or 53BP1 (Figure 4a). When we used
shRNA vectors targeting ARNTL, RBCK1 and TNIP1 we observed
a decrease in p21
CIP1 levels for those shRNA vectors that
produced colonies at 39uC, but not for shRNA vectors that failed
to produce colonies (Figure 4a–c).
To be sure that the decrease in p21
CIP1 protein levels were
caused by decreased p21
CIP1transcription we also measured
p21
CIP1 mRNA levels by QRT-PCR (Figure 4d). All shRNAs that
could produce colonies at 39uC also showed a decrease in p21
CIP1
mRNA. This result suggests that the knockdown of ARNTL,
RBCK1 and TNIP1 leads to a decreased transcriptional activity of
p53 towards its target p21
CIP1.
Recently multiple reports have discussed the relationship
between cancer and circadian rhythm [24–26]. ARNTL is a core
component of circadian rhythm transcriptional machinery
[20,27]. ARNTL binds to CLOCK and together they regulate
expression of 1,000s of genes in a circadian timing [28,29]. Genes
regulated in a circadian fashion are involved in cell cycle,
detoxification and other processes [30]. Therefore we decided to
test if ARNTL is involved in the regulation of p21
CIP1 expression
in other cell systems.
Reduced p21
CIP1activation after DNA damage in HCT116
cells with ARNTL knockdown
Normal human cells arrest either in G1 or S phase of the cell
cycle after encountering DNA damage to repair the DNA, thereby
preventing accumulation of mutations in the genome of daughter
cells. The G1 phase cell cycle arrest is p53 dependent and mainly
executed by the CDK inhibitor p21
CIP1 [31,32] . To investigate if
ARNTL is also required for the p21
CIP1 activation after DNA
damage, we infected U2OS osteosarcoma derived cells with
different shRNAs targeting ARNTL. The cells were incubated to
allow knockdown to take affect, after which cells were irradiated to
inflict DNA damage and monitored for p21
CIP1 activation. When
we compared cells that were infected with a shRNA vector
targeting p53 to cells infected with a control shRNA vector, we
observed lower p53 and p21
CIP1levels after c-radiation. In the cells
infected with ARNTL knockdown vectors we also observed lower
p21
CIP1protein levels, but p53 protein levels were unaffected
(Figure 5a). This observation suggests that ARNTL can modulate
the activity of p53 towards its target p21
CIP1. However, we cannot
distinguish between a specific effect of ARNTL on p21
CIP1and a
more general effect of ARNTL on p53 transcriptional activity.
ARNTL knockdown also allows bypass a p19
ARF induced
growth arrest
As the BJtsLT cells are quite artificial due to the presence of the
SV40 T viral oncogene, we also investigated if ARNTL knockdown
could bypass a more physiological p53-induced cell cycle arrest.
To address this, we used cells in which we can activate p53 by
over-expression of p19
ARF. p19
ARF inhibits MDM2 function
thereby leading to an increase of p53 protein and activation of
target genes [33]. Activation of p19
ARF leads to a stable p53-
dependent cell cycle arrest [34]. To test if ARNTL knockdown can
also rescue a p19
ARF-induced cell cycle arrest, we infected U2OS
cells with the shRNAs targeting ARNTL. After knockdown had
taken effect the cells were super-infected with a p19
ARF encoding
retrovirus. We observed that cells with knockdown of p53 or
Figure 2. Colony formation ARNTL, RBCK1 and TNIP1 shRNA
vectors. Cells were infected with shRNA vectors targeting ARNTL, RBCK1
and TNIP1 and control shRNA vectors targeting GFP, p53, 53BP1 and p21.
Cells wereinfected at32uC and shifted to39uC 2 days after infection.After
three weeks culture at 39uC, the cells were fixed and stained.
doi:10.1371/journal.pone.0004798.g002
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CIP1 continue proliferation after the forced expression of p19
ARF
(Figure 5b), knockdown of ARNTL also allows cells to proliferate
after p53 activation by p19
ARF (for knockdown see figure 5c). This
result suggests that ARNTL expression is required for the anti-
proliferative response of 19
ARF activation. When ARNTL levels are
low, the cells escape this arrest.
Figure 3. Barcode identified shRNA vectors suppress protein and mRNA levels of their targets. a) QRT-PCR for ARNTL in BJtsLT cells.
BJtsLT cells were infected with indicated shRNA vectors. Samples for RNA isolation were taken 8 days after shift to 39uC. b) QRT-PCR for RBCK1 in
BJtsLT cells. BJtsLT cells were infected with indicated shRNA vectors. Samples for RNA isolation were taken 8 days after shift to 39uC. c) QRT-PCR for
TNIP1 in BJtsLT cells. BJtsLT cells were infected with indicated shRNA vectors. Samples for RNA isolation were taken 8 days after shift to 39uC. d) Flag-
ARNTL together with the shRNA vectors targeting ARNTL were transiently transfected in Phoenix cells. Extracts were immunoblotted using Flag and
CDK4 (control) antibodies. e) BJ cells were infected with the indicated shRNA vectors and Extracts were immunoblotted using TNIP1 and CDK4
(control) antibodies.
doi:10.1371/journal.pone.0004798.g003
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CIP1activationdoesnotrequireARNTL
The results described above suggest a role for ARNTL in the
regulation of p21
CIP1 expression by p53. However they do not rule
out that ARNTL controls p21
CIP1activation in a general fashion,
independent of p53. To test this possibility we made use of small
molecule HDAC inhibitors (HDACi). These HDACi cause
induction of p21
CIP1 in both a p53 dependent and p53 independent
manner [35–38]. In order to study the effect of ARNTL on p53
independent activation of p21
CIP1,w em a d eu s eo faH C T 1 1 6p 5 3
knockout cell-line (HCT116 p53
2/2) and the HDACi PXD101
(BelinostatH) [32]. When these HCT116 p53
2/2 cells are treated
with PXD-101, a strong induction of p21
CIP1 is observed (Fig5d and
e). HCT116 p53
2/2 cells infected with a shRNA vector against
p21
CIP1 show reduced p21
CIP1 protein levels after PXD-101
treatment. However, cells infected with a shRNA targeting ARNTL
do not show any alteration in the induction of p21
CIP1 protein levels
following HDACi treatment. Thus the p53-independent induction
of p21
CIP1 by HDACi is not dependent on ARNTL. From this we
conclude that ARNTL isnot generally requiredfor p21
cip1induction,
but does affect the capacity of p53 to activate p21
CIP1 expression.
Discussion
The screening of large-scale RNAi libraries has been used
increasingly over the last years to identify the specific functions of
genes in cellular pathways, networks and mechanisms. Here we
describe the screening of a complex RNAi library to identify genes
that were previously unknown to regulate a p53-dependent cell
cycle arrest.
We have used the RNAi barcode technique to screen a human
shRNA library containing ,24,000 vectors targeting ,8,000
genes. Using this approach, we were able to rapidly identify
shRNAs that allow bypass of a p53 dependent cell cycle arrest. In
total we confirmed that 32 out of the 37 genes that were identified
by the barcode screen could indeed prevent cells from entering
into a p53 dependent cell cycle arrest. However, only 5 of these 32
genes were targeted by two independent shRNAs. Two out of
these five genes (TP53BP1 and p21
cip1) are well-known to be
involved in p53 signaling. However the other three genes (TNIP1,
RBCK1 and ARNTL) were previously not known to be involved in
the p53 pathway.
The three newly identified genes all affect the induction of the
p53 target gene p21
CIP1 but no change in p53 protein stability is
observed after ARNTL, TNIP1 or RBCK1 knockdown. Impor-
tantly, p21
CIP1 knockdown alone is sufficient to rescue cells from
the p53 induced cell cycle arrest. This observation indicates that
the rescue of the p53 induced cell cycle arrest by ARNTL,
RBCK1 or TNIP1 knockdown is the result of a lack of p21
CIP1
induction by p53.
The activity of p53 has been mainly attributed to its role as
transcription factor with tumor suppressive capacities. Therefore, we
assessed ifanyofthe genesidentifiedinourscreenhad beenlinked to
transcription before. TNIP1 was originally identified as an inhibitor
ofNF-kBsignaling [22,39].AlthoughitwasshownthatTNIP1over-
expression inhibits the transcriptional activity of the NF-kB
heterodimer it is believed that this is an indirect effect through an
currentlyunknownmechanism.TheubiquitinE3ligaseRBCK1has
been reported to regulate and ubiquitinate several proteins [21,40–
42]. Although experiments have been performed that suggest a role
for RBCK1 in transcription [43] a clear role for RBCK1 in
regulating transcription has not been reported up till now. This
picture is different for ARNTL which is known to be the central
transcription factor in regulating circadian rhythm. The critical role
of ARTNL in circadian rhythm was demonstrated by the
construction of the knockout mouse. Mice that are deficient for
ARNTL are unable to maintain a circadian rhythm in constant
darkness [20]. In addition, the ARNTL knockout mouse also suffers
from premature aging [44]. In recent years, many other processes
have been shown to be regulated in a circadian fashion. Most
importantly it was shown that the mammalian cell cycle is controlled
by circadian rhythm [45]. The possible involvement of circadian
rhythm in cancer results from studies of the Period 2 knockout
mouse.This mouse is prone to develop tumors after radiation. Later
it was shown that also the Period 1 protein can regulate cell cycle
checkpoints [24–26]. Interestingly both Period 1 and 2 are bona-fide
transcriptional targets of ARNTL.
For the induction of target genes ARNTL must form a
heterodimer with the CLOCK protein [28]. Target genes of the
CLOCK/ARNTL heterodimer include the Period 1, 2 and 3 and
Cryptochromes (Cry 1 & 2) [46]. The increased abundance of Period
and Cryptochrome proteins [47] induces a negative feedback loop
that ultimately shuts down transcription by the CLOCK/ARTNL
heterodimer. When the concentration of Period and Crypto-
chrome decreases due to proteasomal degradation the CLOCK/
ARNTL complex can initiate another round of transcription
thereby completing a cycle of circadian rhythm.
Another transcriptional target of the CLOCK/ARNTL is the
CDK inhibitor p21
CIP1 which is also regulated in a circadian
manner [48]. We show here that ARNTL knockdown in human
Figure 4. Knockdown of ARNTL, TNIP1 and RBCK1 prevents
p21
CIP1inductionin BJtsLT cells.BJtsLTcells were infected at 32uCa n d
shiftedto39uCforcolonyformation.After14daysofculturingat39uC cells
were harvested, protein lysates were prepared and subjected to western
blot for p53, CDK4 (control) and p21
CIP1 (Figure 4a–c). Additionally, total
RNA was isolated and used for QRT-PCR for p21
CIP1 (Figure 4d).
doi:10.1371/journal.pone.0004798.g004
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CIP1 after p53 activation and
overrides a p53-dependent cell cycle arrest. The effect on the
induction of p21
CIP1 is in contrast with previous reports on the
p21
CIP1 regulation in ARNTL knockout mice [48]. In these
animals ARNTL is required for the circadian expression of p21
CIP1.
This discrepancy might be explained by differential regulation of
the p21
CIP1 promoter in mice or man. In particular, this difference
may arise from stress signals differences from in vitro versus in vivo
conditions. Nevertheless, our data clearly indicate that there is a
link between the regulation of circadian rhythm and the control of
p53 activity in human cells.
Conclusions
By screening a large scale RNAi library in human cells we have
identified three novel genes that can regulate p53 function. Loss of
expression for each of three genes results in a decreased ability of
p53 to activate p21
CIP1 expression. Importantly, we showed that
ARNTL is required for the p53-dependent induction of p21
CIP1 in
Figure 5. ARNTL regulates p21
CIP1 expression. a) Knockdown of ARNTL inhibits radiation induced p21
CIP1 induction. U2OS cells were infected
with the shRNA vectors as indicated. Cells were seeded and irradiated with 20 Gy of c-radiation. After o/n incubation cells were lysed and lysates
were subjected to western blot using antibodies for p53, CDK4 (control) and p21
CIP1. b) Knockdown of ARNTL can also rescue a p19-induced cell cycle
arrest. U2OS cells were infected with the indicated shRNA vectors followed by a super-infection with p19ARF-RFP virus. Cells were seeded and
incubated for three weeks. After three weeks the infected cells were fixed and stained. c) Knockdown of ARNTL in U2OS cells (Fig 5b) was quantified
by QRT-PCR. d) ARNTL knockdown is not involved in p53 independent p21
CIP1 induction. HCT116 wt and p53
2/2 cells were infected with knockdown
vectors targeting p53, p21
CIP1 and ARNTL. Cells were treated with 0.5 mM PXD101 for 16 hrs. Cells were then lysed and lysates were subjected to
western analysis for p53, CDK4 (control) and p21
CIP1. e) Quantification of p21 protein levels in the western blot in figure 5c using IMAGE J software.
doi:10.1371/journal.pone.0004798.g005
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p19
ARF-induced cell cycle arrest and a DNA damage mediated cell
cycle arrest. We conclude that ARNTL suppression affects the
ability of p53 to induce a cell cycle arrest upon cellular stress
signals such as DNA damage.
Materials and Methods
Cell lines & culture conditions
BJtsLT cells were cultured in medium that consisted of DMEM
75% / M199 25% supplemented with 10% FCS, Penicillin and
Glutamine. BJtsLT cells were cultured at 32uCi n5 %C O 2. U2OS
and Phoenix cells were cultured in DMEM supplemented with
10% FCS, Penicillin and Glutamine. U2OS and Phoenix cells
were cultured at 37uCi n5 %C O 2.
Plasmids and library
Expression plasmid for ARNTL was generated by PCR from a
cDNA library and subsequent cloning the PCR product into
pCR3-Flag. The P19-RFP construct was described previously
[11]. The construction of the library was described previously
[11]. Briefly, the NKI shRNA library was designed to target 7914
human genes, using three shRNA vectors for every targeted gene,
cumulating in a total of 23,742 shRNA vectors. The shRNAs are
cloned into a retro-viral vector to enable infection of target cells.
Retroviral infection
Phoenix cells were transfected using calcium phosphate method.
Viral supernatant was cleared through a 0.45 mM filter. Cells were
infected with the viral supernatant in presence of polybrene (8 mg/
ml). The infection was repeated twice.
shRNA barcode screen
To screen the NKI shRNA library we reasoned that we would
need 100 fold coverage of the library to get a good representation
of all 23,742 shRNA vectors present in the library. BJtsLT cells
were infected with the NKI shRNA library. Two days after
infection cells were plated at 150,000 cells/15 cm dish. In total
2610
6 cells were shifted to 39uC, equal number of cells were kept
at 32uC. Cells at 32uC were harvested after 5 days. Cells at 39uC
were harvested at 21 days after shift. From both populations
gDNA was isolated using DNAzol (Invitrogen). The shRNA
cassettes were amplified by PCR. The PCR product was used for
in vitro RNA synthesis. RNA was labeled with Cy3 or Cy5
(Kreatech) and hybridized on a microarray. Quantification of the
resulting fluorescent images was performed with Imagene 5.6
(BioDiscovery), local background was subtracted, and the data
were normalized and
2log transformed. Additional information on
barcode screens can be found at http://www.screeninc.nl.
Colony formation assay
Cells were infected with retroviral supernatant. Two days after
infection the cells were seeded at 50,000/10 cm dish and shifted to
39uC. Cells were cultured at 39uC for approx 21 days. When
colonies appeared cells were fixed in MeOH/HAc (3:1) and
subsequently stained (50% MeOH/10% HAc/0.1% Coomassie).
Western blotting
Cell lysates were separated using 10% SDS-PAAGE. Proteins
were transferred to PVDF membrane and incubated with primary
antibody as indicated. Primary antibodies were detected using a
secondary HRP-conjugated antibody. Antibodies used for these
studies: Flag (M2; Sigma), TNIP1 (1A11E3; Zymed), CDK4 (C-




Total RNA was isolated using TRIzol (Invitrogen). From the
total RNA cDNA was generated using Superscript II (Invitrogen)
using random primers (Invitrogen). cDNA was diluted and QRT
reaction was performed using Taqman probes (Applied Biosys-
tems). All QRT reactions were run in parallel for GAPDH to
control of for input cDNA. The QRT reactions were run at a
AB7500 Fast Real Time PCR system (Applied Biosystems). Results
shown are a representative of three independent experiments.
p21
CIP1 induction by c-radiation and PXD101
For the p21
CIP1 induction by radiation 50,000 cells were seeded
per 6-well. HCT116 p532/2 cells were irradiated with 20 Gy c-
radiation from a Cs-137 source. Cells were incubated for 16 hrs
and lysed. For the p21
CIP1 induction by PXD101 50,000 cells were
seeded/6-well and treated with 0.5 mM PXD101 for 16 hrs after
which the cells were lysed and protein lysates were subjected to
western analysis.
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